4D Presents Positive Interim Data from Phase 1/2 Trial in Wet AMD

 

• Intravitreal 4D-150 was well-tolerated with no inflammation in 14 of 15 patients and only trace mixed cells at a single timepoint in one patient; no dose-limiting toxicities, treatment-related serious adverse events (SAE) or hypotony reported across all three dose cohorts with follow-up of 24 – 64 weeks
  

• Dose response demonstrated in favor of high dose 3E10 vg/eye, including superior reduction in supplemental anti-VEGF injections and mean central subfield thickness (CST) reduction

• 80% of patients in the 3E10 vg/eye high dose cohort did not require supplemental anti-VEGF injections through 36 weeks following a single intravitreal dose of 4D-150

• Clinically-meaningful improvement in mean CST of -92 µm at 36 weeks, and stable best corrected visual acuity (BCVA), following a single 3E10 vg/eye intravitreal dose of 4D-150

• Phase 2 Dose Expansion stage of PRISM trial (n=50 patients) more than 50% enrolled; enrollment completion expected Q3 this year

• Company to host live webcast today at 8:00 a.m. ET with retinal expert Arshad Khanani, M.D., M.A., FASRS

4D Molecular Therapeutics will host a webcast today, Thursday, April 27, 2023 at 8:00 a.m. Eastern Time to discuss clinical data and development plans. Dr. Arshad Khanani will also join today's webcast.

Title:	4D-150 Phase 1/2 PRISM Interim Clinical Data Webcast and Q&A
Date/Time:	Thursday, April 27, 2023, 8:00 a.m. ET
Registration:	Link

An archived copy of the webcast will be available for up to one year by visiting the “Investors & Media” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

https://finance.yahoo.com/news/4dmt-presents-positive-interim-data-110000150.html